While the FDA is not required to follow the panel's recommendation, the agency's final decision on Orkambi is crucial to Vertex's future.
Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways
A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.
UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals
Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks
FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.
In a bid to compete with CVS Caremark, pharmacy retailer Rite Aid has purchased pharmacy- benefit manager Envision Pharmaceutical Services.
Former FDA chief tells court J&J knew of Risperdal risk, pay-for-delay deals get new court criteria, lawmakers may declare pharmacists healthcare providers.
Express Scripts takes aim at high-priced cancer drugs; FDA panel recommends approval for Astellas orphan drug; GSK Ebola Vaccine could touch down in Liberia as early as next week.